The staphyloccous aureus eap protein activates expression of proinflammatory cytokines by Scriba, Thomas J. et al.
  Published Ahead of Print 10 March 2008. 
2008, 76(5):2164. DOI: 10.1128/IAI.01699-07. Infect. Immun. 
Phillips, Andrew K. Sewell and Ruth C. Massey
Thomas J. Scriba, Sophie Sierro, Eric L. Brown, Rodney E.
 
Cytokines 
Activates Expression of Proinflammatory 
 Eap ProteinStaphyloccous aureusThe 
http://iai.asm.org/content/76/5/2164
Updated information and services can be found at: 
These include:
REFERENCES
http://iai.asm.org/content/76/5/2164#ref-list-1
This article cites 20 articles, 7 of which can be accessed free at:
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 February 24, 2014 by Cardiff Univ
http://iai.asm
.org/
D
ow
nloaded from
 
 o
n
 February 24, 2014 by Cardiff Univ
http://iai.asm
.org/
D
ow
nloaded from
 
INFECTION AND IMMUNITY, May 2008, p. 2164–2168 Vol. 76, No. 5
0019-9567/08/$08.000 doi:10.1128/IAI.01699-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
The Staphyloccous aureus Eap Protein Activates Expression of
Proinflammatory Cytokines
Thomas J. Scriba,1 Sophie Sierro,1 Eric L. Brown,2 Rodney E. Phillips,1
Andrew K. Sewell,3 and Ruth C. Massey4*
Nuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford OX1 3SY,
United Kingdom1; University of Texas School of Public Health, 1200 Herman Pressler, Houston, Texas 770302; Department of
Medical Biochemistry and Immunology, Cardiff University School of Medicine, Henry Wellcome Building, Heath Park,
Cardiff CF14 4XN, United Kingdom3; and Department of Biology and Biochemistry, University of Bath,
Claverton Down BA2 7AY, United Kingdom4
Received 20 December 2007/Returned for modification 8 February 2008/Accepted 26 February 2008
The extracellular adhesion protein (Eap) secreted by the major human pathogen Staphylococcus aureus is
known to have several effects on human immunity. We have recently added to knowledge of these roles by
demonstrating that Eap enhances interactions between major histocompatibility complex molecules and
human leukocytes. Several studies have indicated that Eap can induce cytokine production by human periph-
eral blood mononuclear cells (PBMCs). To date, there has been no rigorous attempt to identify the breadth of
cytokines produced by Eap stimulation or to identify the cell subsets that respond. Here, we demonstrate that
Eap induces the secretion of the proinflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor
alpha (TNF-) by CD14 leukocytes (monocytes and macrophages) within direct ex vivo PBMC populations
(note that granulocytes are also CD14 but are largely depleted from PBMC preparations). Anti-intercellular
adhesion molecule 1 (CD54) antibodies inhibited this induction and implicated a role for this known Eap
binding protein in cellular activation. IL-6 and TNF- secretion by murine cells exposed to Eap was also
observed. The activation of CD14 cells by Eap suggests that it could play a significant role in both septic shock
and fever, two of the major pathological features of S. aureus infections.
Staphylococcus aureus is a major human pathogen, with
strains that are resistant to antibiotics emerging worldwide
(e.g., the methicillin- and vancomycin-resistant S. aureus
strains) (13, 15). While it is largely a commensal organism
living asymptomatically in the nasal cavities of a large propor-
tion of the human population (17), it also causes infections that
range widely in both body site and severity. Skin infections
such as impetigo, folliculitis, and boils can be caused by S.
aureus, as can life-threatening illnesses such as endocarditis,
osteomyelitis, and septicemia (13). Despite its largely commen-
sal lifestyle, this organism expresses a large number of factors
such as toxins, adhesins, invasins, and modulins that contribute
to its pathogenicity. These factors allow the bacteria to attach
to and invade host tissues, causing widespread damage, and
they also facilitate evasion of the host’s protective immune
responses (5, 19).
S. aureus secretes a multirepeat protein known as the extra-
cellular adhesion protein (Eap) (7) or the major histocompat-
ibility complex (MHC) analog protein (Map) (9). This is a
member of the secreted expanded repertoire adhesive mole-
cule (SERAM) family (3), and a recent study has shown that at
least 98% of S. aureus strains secrete a form of this protein (1).
With some strain-to-strain variation, the Eap consists of four to
six repeats of approximately 110 amino acids (1). Structural
studies have revealed homology between the individual repeats
of Eap and the C-terminal half of superantigens such as toxic
shock syndrome toxin 1 (TSST-1) and staphylococcal entero-
toxin B, suggesting this protein may have superantigenic activ-
ity (6). A recent study comparing the activity of Eap to that of
a known superantigen (TSST-1) showed that while similarities
exist between the two proteins in relation to their ability to
cross-link molecules, Eap’s activity was not as specific as that of
TSST-1 (14).
The ability of Eap to bind many host factors is well estab-
lished (7), and the potential downstream effects of these inter-
actions, which include T-cell modulation (11) and the preven-
tion of leukocyte extravasation (2), have suggested that Eap
may act as an anti-inflammatory factor. This anti-inflammatory
activity has led to the proposition that this protein may be used
to treat diseases such as multiple sclerosis (20). To determine
what effects Eap’s cross-linking activity has on inflammatory
cytokine expression by human cells, we incubated Eap with
human peripheral blood mononuclear cells (PBMCs) and
found that it resulted in the induction of proinflammatory
cytokine expression (interleukin 6 [IL-6] and tumor necrosis
factor alpha [TNF-]). Despite its structural similarity to su-
perantigens, Eap’s proinflammatory activity was not dependent
upon its cross-linking activity where a single repeat was active.
We observed no cytokine secretion by T cells; instead, CD14
cells were responsible for IL-6 and TNF- secretion. Produc-
tion of these proinflammatory cytokines was reduced by the
preincubation of cells with anti-intercellular adhesion mole-
cule 1 (ICAM-1; CD54) antibodies, suggesting that this ligand
is involved in Eap-induced activation. The effects of Eap on
murine cells were tested with three different cell populations,
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and the degree of proinflammatory activation was found to
vary depending on the anatomical site from which the cells
were harvested.
MATERIALS AND METHODS
Isolation of human PBMCs. Blood was collected from healthy volunteers.
PBMCs were isolated from heparinized blood by density-gradient centrifugation
over Lymphoprep (Axis Shield). PBMCs were washed in RPMI medium sup-
plemented with 100 units/ml penicillin, 100 units/ml streptomycin, and 2 mM
L-glutamine (Sigma-Aldrich).
Antibodies. Anti-CD14-PerCP (BD Biosciences), anti-IL-6-phycoerythrin
(PE), and anti-TNF--PE antibodies (Caltag-Medsystems Ltd.) were used in this
study. Anti-CD14, anti-CD19, anti-CD54, and anti-CD66 antibodies were pur-
chased from Serotec and used at a concentration of 50 g/ml.
Native and recombinant Eap purification. Native and pseudo-Eap were pu-
rified from the Newman, mAH12, and mAH12(pCXEap) strains as described
previously (14). As such, protein preparations from Newman and mAH12
(pCXEap) contain full-length Eap protein and the preparation from mAH12
contains no Eap (the negative control, referred to as pseudo-Eap). Recom-
binant forms of Eap repeat subunits (Eap19 and Eap10, also known as Map19
and Map10) were purified as described previously (12). Eap19 consisted of
amino acids Gln20 to Gln240 and Eap10 of amino acids Gln20 to Gln130 of
the mature peptide. All protein preparations were tested for the presence
of contaminating endotoxins by using an E-TOXATE kit from Sigma in
accordance with the manufacturer’s instructions and found to contain unde-
tectable levels of endotoxin.
Cytokine secretion assay. Cells were resuspended in RPMI medium contain-
ing 10% fetal calf serum (FCS). Cells (2  105 per 96-well U-bottom plate well)
were incubated in the presence or absence of the indicated concentration of Eap
protein preparations for 6 h at 37°C with 5% CO2. Phytohemagglutinin (PHA; 5
g/ml; Sigma-Aldrich) was used as a positive control. Assays were performed in
triplicate and repeated three times with PBMCs isolated from different donors.
Following its incubation, the supernatant was assayed for IFN-, TNF-, IL-2,
IL-4, IL-6, and IL-10, using a Th1/2 Cytometric Bead array kit (BD Biosciences)
according to the manufacturer’s instructions. The results were averaged and are
presented as either the mean concentration in the supernatant ( standard error
of the mean [SEM]) or as the mean induction (n-fold) of the level of cytokine
expressed by the cells in the absence of Eap (SEM). Student’s t test was used
to determine P values. Antibody blocking was performed by incubating the
PBMCs in 50 g/ml of the indicated antibody for 30 min prior to the addition of
5 g/ml Eap19.
Intracellular cytokine staining assay. Fresh PBMCs (1  106) were washed
and resuspended in RPMI medium supplemented with 100 units/ml penicillin,
100 units/ml streptomycin, and 2 mM L-glutamine and 10% FCS. Cells were
incubated in the presence or absence of Eap10 protein (10 g/ml) (this prepa-
ration of Eap was used as the others aggregated the cells, making the study of
individual cells and their fluorescence intensities difficult) for 4 h at 37°C with 5%
CO2. Brefeldin A (10 g/ml) was added after 1 h, and following the incubation,
the cells were washed in cold phosphate-buffered saline (PBS), stained with
surface marker antibodies, washed again, permeabilized with Cytofix/Cytoperm
(BD Biosciences), and stained with antibodies to intracellular proteins. Experi-
ments were performed in triplicate and repeated three times with PBMCs iso-
lated from different donors.
Isolation and activation of murine cells. Mice were bred and maintained in a
conventional pathogen-free animal facility. All experiments were performed
using age-matched female BALB/c mice and with the permission of the Home
Office, according to the Animals Scientific Procedures Act of 1986. Spleens were
harvested from naı¨ve BALB/c mice, and single-cell suspensions were prepared.
Blood was collected in heparin, and red blood cells were lysed by using ACK
lysing buffer (Invitrogen). To obtain peritoneal macrophages, mice were sacri-
ficed and peritoneal lavage was performed with 10 ml of sterile isotonic saline
(PBS), and total cell numbers were counted. All cells were resuspended in RPMI
medium supplemented with 100 units/ml penicillin, 100 units/ml streptomycin,
and 2 mM L-glutamine (Sigma-Aldrich). For the assay, 1  106 splenocytes, 2 
105 blood cells, and 2  105 peritoneal macrophages were incubated with Eap,
pseudo-Eap, medium only, or lipopolysaccharide (LPS; as the positive control)
for 6 h. The cell supernatant was then collected and assayed for IL-12p70,
TNF-, IFN-, MCP-1, IL-10, and IL-6, using a mouse inflammation bead array
kit (BD Biosciences).
RESULTS
Eap induces the expression of proinflammatory cytokines by
human PBMCs. Previous studies have found that the Eap pro-
tein can induce the expression of IL-4 by PBMCs (8). Based on
these and other studies, it has been suggested that Eap skews the
immune response toward a Th2 rather than a Th1 immune re-
sponse (7, 11). To confirm this, we tested the supernatant of
human PBMCs exposed to a range of native Eap protein concen-
trations (Fig. 1) for the presence of cytokines, using a Th1/Th2
cytometric bead array. A dose-dependent effect of Eap on the
secretion of several cytokines was observed (Fig. 1). In agreement
with a previous study (8), we saw Eap-induced induction of IL-4
(P  0.02); however, substantially larger amounts of IL-6 and
TNF- were induced (P  0.01). These findings do not support
the assertion that Eap induces a Th2-type response.
FIG. 1. Eap induces the expression of proinflammatory cytokines by PBMCs. Cytokine production was measured with the Th1/Th2 cytometric
bead array in PBMC supernatant and is expressed as the increased (fold) expression relative to the PBMCs incubated in medium alone. The native
Eap protein from the Newman strain induces the expression of TNF- and IL-6 (proinflammatory cytokines) by PBMCs at high levels.
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To verify that IL-6 and TNF- secretion induction was Eap
specific, cytokine production was assayed after incubation with
equimolar concentrations of full-length native Eap (from the
wild-type Newman strain [10 g/ml]), pseudo-Eap (from
mAH12, a Newman mutant lacking Eap), full-length Eap iso-
lated from the complemented mutant strain [mAH12(pCXEap);
10 g/ml]; and a recombinant form of the first two repeats of Eap
(Eap19 [3 g/ml] and a recombinant form of the first repeat of
Eap [Eap10; 1.5 g/ml]). All preparations containing Eap protein
induced the secretion of high levels of IL-6 and TNF- (Fig. 2),
while pseudo-Eap from the knockout strain did not (P  0.01).
Eap10-induced (a single repeat of Eap) expression suggests a
direct effect of Eap binding rather than an effect resulting from
the cross-linking of molecules or cells, as two or more repeats of
Eap are required for this (14). These data demonstrate that Eap
can act as a proinflammatory mediator.
Eap activates the CD14 leukocytes. To determine which
cells are activated by Eap, intracellular cytokine staining was
performed with PBMCs following their incubation with Eap10
(1 g/ml). It was necessary to use the single repeat of Eap for
these experiments as cell aggregation was often observed when
multiple-repeat forms of Eap were used. Figure 3 shows the
expression levels of TNF- and IL-6 in PBMCs with and with-
out Eap stimulation. Costaining cells with fluorochrome-
labeled anti-CD14 antibodies showed that CD14 cells (i.e.,
monocytes; note that granulocytes are also CD14 but are
largely depleted from PBMC preparations) express IL-6 and
TNF- after Eap stimulation. CD14	 cells, such as T cells,
were not expressing these cytokines.
Anti-ICAM-1 antibodies block cell activation by Eap. A pre-
vious study demonstrated that Eap binds to ICAM-1 (CD54)
FIG. 2. Eap alone is responsible for the induction of cytokine ex-
pression, and a single repeat is sufficient. PHA, control mitogen; Eap
purified from Newman (the wild-type S. aureus strain); pseudo-Eap
purified from the mAH12 strain lacking eap; Eap purified from the
complemented mAH12(pCXEap) strain; Eap19, recombinant double
repeat of Eap; and Eap10, recombinant single repeat of Eap.
FIG. 3. CD14 cells express IL-6 and TNF- following stimulation by Eap. Intracytoplasmic staining was performed to determine which cells
were being activated by Eap. The panels on the left show TNF- expression in unstimulated (upper plot) and Eap10-stimulated (lower plot)
PBMCs. The panels on the right show IL-6 expression in unstimulated (upper plot) and Eap10-stimulated (lower plot) PBMCs. Only CD14 cells
produce proinflammatory cytokines in response to Eap.
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on cell surfaces (2). We used antibodies to this protein to
determine whether this ligand played a role in the induction of
CD14 cells to produce IL-6 and TNF- by Eap10. PBMCs
were incubated with Eap10 (1 g/ml) following incubation in
the presence of different antibodies. Blocking antibodies (the
same isotype as our anti-CD54 antibody) to CD14, CD19, and
CD66 had a small effect on IL-6 expression but no effect on
TNF- expression (P  0.8), but incubation with anti-ICAM-1
antibody significantly reduced IL-6 and TNF- expression (P 
0.01) (Fig. 4). The anti-CD54 antibody had no effect on the
proinflammatory activity of PHA or LPS, suggesting that the
effect is specific. This suggests that the ICAM-1 molecule is
involved in Eap-mediated induction of proinflammatory cyto-
kine expression by CD14 cells.
Eap can induce IL-6 and TNF- expression by murine cells.
To determine whether the induction of proinflammatory cyto-
kines by Eap was specific to humans, the ability of Eap to
stimulate the production of IL-6 and TNF- by three different
murine cell populations was tested (Fig. 5). Cells harvested
from blood and spleens were exposed to 5 g/ml Eap. The
level of cytokine production by the peritoneal macrophages
following exposure to 5 g/ml Eap was beyond the levels of
detection of our assay, and so the data from the exposure of
these cells to 1 g/ml of Eap are shown. IL-6 and TNF- were
detected in all samples incubated with Eap, with the peritoneal
macrophages showing the highest level of cytokine production.
It should be noted that of the three cell preparations, the
peritoneal macrophages contained the highest proportion of
CD14 cells.
DISCUSSION
Inflammation is a local tissue response to infection or dam-
age. It is a complex process that leads to an elevated blood
supply and an increase in vascular permeability in the blood
vessels surrounding the affected area. Included in the series of
events leading to inflammation is an increased ICAM-1 expres-
sion in the surrounding vascular endothelium, resulting in in-
creased adhesion and migration of leukocytes to the affected
area. The expression of proinflammatory cytokines is also in-
creased, resulting in a cascade of events that culminate in
inflammation. Previous studies of the activity of the Eap pro-
tein suggest that it is anti-inflammatory due to its ability to bind
ICAM-1 and as a consequence to block leukocyte recruitment
to an inflamed area (2). It has also been reported that Eap
induces the expression of the anti-inflammatory cytokine IL-4
by human cells (8).
We have previously shown that Eap has the ability to in-
crease the binding of MHC molecules to human leukocytes
(14), and here we examined what effects this might have on
cytokine expression by human cells. Using a Th1/Th2 cytokine
bead array, we also noted an increase in IL-4; however, the
increase in expression of the proinflammatory cytokines IL-6
and TNF- was substantially higher. Technology has advanced
such that the expression levels of multiple cytokines can be
simultaneously assayed in a single experiment. The former
study reports only on the examination of expression of IL-4
and IFN- and so would not have detected any increase in IL-6
or TNF- expression.
Immunomodulatory proteins expressed by S. aureus can
have human-specific activity (4), and we initially believed that
the explanation for the apparent conflict between our findings
of proinflammatory activity and the anti-inflammatory activity
reported in murine studies (2, 20) could be explained by such
host specificity. We found some body site specificity in murine
cellular responses to Eap, a likely reflection of the proportion
of CD14 cells present, but conclude that Eap also appears to
be proinflammatory in mice. It is likely that the expression of
proinflammatory cytokines and the downstream effects of this,
such as the induction of fever, were beyond the remit of the
murine studies that established the anti-inflammatory activity
for this protein. The findings of this study in combination with
FIG. 4. Anti-ICAM-1 (CD54) antibodies block Eap-induced IL-6
and TNF- secretion. PBMCs were preincubated with a range of
antibodies to identify the ligand used by Eap to induce cytokine ex-
pression. Only anti-CD54 (ICAM-1) antibodies significantly reduce
cytokine expression.
FIG. 5. Eap induced TNF- and IL-6 secretion by murine cells. Murine cells were harvested from blood, from the peritoneal cavity, and from
the spleens of mice. All three populations were tested for the ability to secrete IL-6 and TNF- upon exposure to native Eap protein relative to
that of the negative pseudo-Eap control. LPS was used as a positive control.
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the previous murine reports show that through interaction with
ICAM-1, the Eap protein can induce an inflammatory re-
sponse through the induction of IL-6 and TNF- and, at the
same time, prevent leukocyte extravasation.
Our previous findings (14) led us to believe that Eap is not
a superantigen, and as further evidence for this, we observed
no cytokine secretion by naive T cells. Activation of T cells by
superantigens requires the cross-linking of MHC class II mol-
ecules with T-cell receptors on the T-cell surface (12). We have
demonstrated that the single-repeat unit present in the Eap10
protein is insufficient to induce such Eap “cross-linking” (14).
In contrast, the Eap10 molecule was sufficient to induce cyto-
kine production by CD14 cells (Fig. 3), suggesting different
requirements for the “cross-linking” and CD14 cell-activating
activities of the Eap protein. Antibody inhibition experiments
(Fig. 4) suggest that ICAM-1 plays a role in the activation of
CD14 cells. However, ICAM-1 is also expressed on some
CD14	 cells (10, 16). These cells do not respond to Eap (Fig.
3), suggesting that additional factors may also be involved in
the Eap-induced activation of cytokine expression by CD14
cells.
In summary, our findings extend those of previous studies by
showing that the Eap protein can induce both human and
murine cells to produce copious amounts of IL-6 and TNF-.
This potential proinflammatory role of Eap has not been ap-
preciated previously and may be significant in vivo. We believe
that the effects of Eap are likely to be highly variable depend-
ing on both the body site and the levels of expression of both
ICAM-1 and Eap. A recent study has found that relative to the
antibodies in healthy individuals, those of Eap were signifi-
cantly higher in patients suffering from infective endocarditis
caused by S. aureus infection (18). This suggests that significant
amounts of Eap must be present in the bloodstream to induce
an antibody response. Although the exact concentration
reached is as yet unknown, we believe that this and other
studies suggest Eap could reach levels sufficient to induce sep-
tic shock and fever. Further in vivo work is required to examine
this and to establish the concentrations of Eap protein in the
bloodstream during infections. This study opens up the intrigu-
ing possibility that Eap-induced activation of CD14 cells in
vivo plays a significant role in disease and that strategies aimed
at preventing such activation may be helpful in treating
patients infected with this increasingly problematic human
pathogen.
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